New session examines rising drug costs and access to care


Arianne Shadi Kourosh, MD

Hear about changes in the health care environment, including the impact of drug pricing, during the new session, “The Impact of Drug Pricing on Access to Care: Demystifying the Landscape” (U013) on Friday, March 4.

The session, presented from 7:30 to 8:30 a.m. in Room 140B, will be directed by Arianne Shadi Kourosh, MD, and co-directed by Elise A. Olsen, MD. Additional invited speakers include Jonathan Jarrow, MD, an FDA senior medical advisor, and Len Nichols, who is a health economist at George Mason University.

As out-of-pocket costs for medications continue to rise, dermatology patients are routinely being denied coverage due to increased utilization of review tools by insurers. Many hurdles now stand in the way to obtaining good medical care, including narrowing drug formularies, prior authorizations, step therapy, and “specialty tiers.” This session will provide a thorough briefing on the current health care environment, and will focus on these aspects:

Elise A. Olsen, MD

Elise A. Olsen, MD

  • Education on the impact of drug pricing
  • Ways that legislative and national agencies, such as CMS, HHS, and the FDA, can influence transparency and develop solutions
  • Strategies dermatologists can use to collaborate with both patients and stakeholders to improve access to medications.

After attending the course, attendees should be able to recognize the market forces behind the shroud of drug pricing; understand how legislature and national agencies can impact drug costs; and recognize the perspectives of lawmakers, physicians, regulatory agencies, and economists to formulate strategies and retain access to treatments despite the barriers of high out-of-pocket costs.

This session will offer 1 CME credit, and is open to all eligible categories; no tuition or ticket is required for admittance.

Return to index